Sign inJoin waitlistJoin the waitlist

Mazyar Shadman

Deputy Chief Medical Officer, Fred Hutch · University of Washington School of Medicine

Credentials: · · · · ·

History

Cellular Immunotherapy · University of Washington School of Medicine
Present
University of Washington School of Medicine
Present
University of Washington School of Medicine
Present

Hematology and Medical Oncology
University of Washington-Seattle Campus
2007–2010
Cleveland Clinic Foundation
2004–2007
Tehran University of Medical Sciences
2000–2004

Research

Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
New England Journal of Medicine · 2023 · Last of 28 authors · 435 citations
Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy
Blood · 2019 · 359 citations
The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells
Blood · 2019 · 306 citations

Ajay Gopal
53 papers
Chaitra Ujjani
50 papers
Brian Till
43 papers
Stephen Smith
35 papers
Brian Hill
33 papers
David Maloney
32 papers
Ryan Lynch
32 papers
Jennifer Brown
31 papers
CT
Cameron Turtle
29 papers
Jordan Gauthier
28 papers · 6 as a fellow
AH
Alex Herrera
27 papers
Nicole Lamanna
26 papers

Clinical trials

Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma
Principal investigator · Recruiting · Phase 2
Fred Hutchinson Cancer Center
2025–2032
Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial
Principal investigator · Recruiting · Phase 2
Fred Hutchinson Cancer Center
2023–2031
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
Principal investigator · Active not recruiting · Phase 1, Phase 2
Fred Hutchinson Cancer Center
2017–2039
HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection
Principal investigator · Withdrawn · Phase 1
Fred Hutchinson Cancer Center
2016